Atlas Trials

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Clinical trial NCT02288377 · TERMINATED

Trial details

NCT number
NCT02288377
Sponsor
Federation Francophone de Cancerologie Digestive
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Start date
2015-01-01
Primary completion
2020-01-01
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.